# Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer

> **NCT02984683** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 23 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** SAR566658 (ACT14884)

## Key facts

- **NCT ID:** NCT02984683
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-23
- **Primary completion:** 2018-09-07
- **Final completion:** 2018-09-07
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Study discontinued considering the limited clinical benefit combined with a higher than expected rate of known non-serious ophthalmological event.
- **Last updated:** 2021-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02984683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02984683, "Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02984683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*